Intraop Medical Inc. Announces Major European Cancer Centers Form IORT Research Consortium.

SANTA CLARA, Calif. -- Intraop Medical, Inc. announced today that a new European body has been formed to study intraoperative radiotherapy ("IORT"). The new body will be called the European Consortium for Research in IORT Studies ("ECRIS"). The founding members of ECRIS are Hospital Gregorio Maranon, Madrid, Spain; Institut Gustave Roussey, Paris France; Centre Oscar Lambret, Lille, France; Catharina Ziekenhuis, Eindhoven, the Netherlands; University of Heidelberg, Heidelberg, Germany; Ospedale Maggiore della Carita of the University of Piemonte Orientale in Novara Italy; European Institute of Oncology, Milan, Italy; University of Torino, Torino, Italy; and Catholic University, Rome, Italy. Also invited to participate in ECRIS are the University of North Carolina at Chapel Hill, North Carolina which will contribute its expertise in IORT radiobiology and its IORT breast protocol, and the University of California at San Francisco, San Francisco, California which has been selected for its recognized expertise in pediatric IORT.

ECRIS will have their first organizational meeting in Novara, Italy in April 2005 to establish the guidelines for their operation. Professor Marco Krengli, Professor and Chief of Radiation Oncology at the University of Piemonte Orientale Medical School in Novara commented, "We are very pleased to host this first meeting of ECRIS. The concept of ECRIS has been very positively received and we expect a number of additional European centers to join our efforts in the near future. Cooperation among European IORT centers will enable us to obtain answers on the proper role of integrating IORT in the management of our cancer patients much more quickly than if we each worked alone. We anticipate that the member institutions involved with ECRIS will grow as more centers develop IORT capability over the next few years."

Intraop Medical will provide logistical support to the participants and to ECRIS. Among the tumor sites that are expected to be studied by ECRIS are pancreatic cancer, rectal cancer, sarcomas, lung cancer, breast cancer, prostate cancer, and pediatric cancer.

ECRIS is unique in that it will facilitate the initiation of prospective studies in IORT. With more than 30,000 cancer patients under treatment each year at the member centers, ECRIS is expected to be able to rapidly accrue IORT patients in their study protocols. Other interested European centers with strong IORT interest and capability will be invited to participate in ECRIS.

About Intraop Medical, Inc.

Intraop Medical, Inc. ("IntraOp") was formed in April 1993 to develop, manufacture, market and service the Mobetron, a mobile electron beam system designed for IORT treatment of cancer, coronary/vascular restenosis and other medical applications. Unlike other IORT systems, the Mobetron uses several patented technologies to allow IORT to be used without requiring shielding of the operating room. The Mobetron can be moved between operating rooms or even between hospitals, thereby increasing the system's utilization and cost effectiveness.

About Intraop Medical Corporation: Intraop Medical, Inc. has entered into a Merger Agreement with Intraop Medical Corporation (OTCBB:IOPM), whereby Intraop Medical Corporation will acquire Intraop Medical, Inc. in a merger. A definitive information statement regarding the merger has been filed with the United States Securities and Exchange Commission. The shareholders of Intraop Medical, Inc. and the principal shareholder of Intraop Medical Corporation have already approved the merger. The merger is expected to be finalized in the next few weeks. Following the merger, the sole business of Intraop Medical Corporation, headquartered in Salt Lake City, Utah, will be that of Intraop Medical, Inc. and the combined company's operations will be conducted from Intraop Medical, Inc.'s Santa Clara, California offices.

This press release contains "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the company to execute its plans. By making these forward-looking statements, the company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.